Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants
- Conditions
- Brain Damage, Chronic
- Registration Number
- NCT00544895
- Lead Sponsor
- Hannover Medical School
- Brief Summary
NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage. The focus of NEOBRAIN is to identify strategies prevention of brain damage mainly observed in preterm newborns. (Copy from www.neobrain.eu)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 600
- Gestational age < 28 weeks
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Brain white matter damage (WMD, defined by MRI ,US, EEG) during stay in NICU and until discharge
- Secondary Outcome Measures
Name Time Method Developmental assessment at 2 years of age
Trial Locations
- Locations (12)
Wilhelmina Children's Hospital
🇳🇱Utrecht, Netherlands
Perinatal Center
🇸🇪Gothenburg, Sweden
Charité, Campus Virchow Klinikum
🇩🇪Berlin, Germany
University Hospital
🇸🇪Lund, Sweden
Hôpital Robert Debré
🇫🇷Paris, France
Hannover Medical School
🇩🇪Hannover, Germany
Fondazione I.R.C.C.S Ospedale Maggiore Policlinico MA.RE.
🇮🇹Milano, Italy
Azienda Ospedaliera Universitaria Senese
🇮🇹Siena, Italy
Hôpital des Enfants
🇨🇭Geneva, Switzerland
Universität Duisburg-Essen
🇩🇪Essen, Germany
Academic Children's Hospital
🇸🇪Uppsala, Sweden
Medizinische Universität Innsbruck
🇦🇹Innsbruck, Austria